<div id="readability-page-1"><p>Scilex (NASDAQ:SCLX - Get Free Report) posted its quarterly earnings data on Friday. The company reported ($22.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($21.76), Zacks reports.</p><h2>Scilex Price Performance</h2><ul><li>Datavault AI's 314% Upside: Huge Potential or Wall Street Mirage?</li></ul><p>Shares of SCLX traded down $0.18 during mid-day trading on Friday, hitting $17.69. The company's stock had a trading volume of 61,732 shares, compared to its average volume of 146,317. The firm has a 50-day moving average price of $19.97 and a 200 day moving average price of $13.12. Scilex has a fifty-two week low of $3.60 and a fifty-two week high of $34.27. The stock has a market capitalization of $134.27 million, a price-to-earnings ratio of -1.11 and a beta of 1.34. </p><h2>Institutional Inflows and Outflows</h2><p>Several institutional investors have recently modified their holdings of the stock. Goldman Sachs Group Inc. lifted its position in shares of  Scilex by 31.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 136,352 shares of the company's stock valued at $34,000 after acquiring an additional 32,449 shares during the last quarter.  Norges Bank acquired a new stake in shares of  Scilex during the second quarter worth $80,000.  Finally, BNP Paribas Financial Markets lifted its holdings in shares of  Scilex by 189.6% during the third quarter. BNP Paribas Financial Markets now owns 7,430 shares of the company's stock valued at $146,000 after purchasing an additional 4,864 shares during the last quarter. Institutional investors own  69.67% of the company's stock. </p><h2>Analyst Upgrades and Downgrades</h2><ul><li>Datavault AI: The New AI Contender Backed by Big Funding</li></ul><p>Separately, Weiss Ratings  restated a &#34;sell (d-)&#34; rating on shares of Scilex in a research report on Wednesday, October 8th. Two analysts have rated the stock with a Hold rating and one  has given a Sell rating to the company's stock. According to data from MarketBeat, the company  has an average rating of &#34;Reduce&#34; and an average price target of $630.00.</p><p><b>Check Out Our Latest Stock Analysis on SCLX</b></p><h2>About Scilex</h2> (Get Free Report)<p>Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Scilex</li><li>How to Calculate Stock Profit </li><li>Are These 3 Oversold Tech Giants Ready to Rebound?</li><li>What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story</li><li>If You Wait for the Dip,  Micron Technology Could Leave You Behind</li><li>Buy P&amp;G Now, Before It Sets A New All-Time High</li><li>3 Stocks Quietly Powering the AI and Tech Revolution</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0NMWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0NMWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Scilex Right Now?</h2><p>Before you consider Scilex, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Scilex wasn't on the list.</p><p>While Scilex currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

SCLX

<p>Scilex (NASDAQ:SCLX) reported a quarterly earnings per share (EPS) of ($22.17), significantly missing the consensus estimate of ($0.41) by $21.76. The company's stock traded down to $17.69, with a market cap of $134.27 million. Institutional investors hold 69.67% of the stock. Analysts have given Scilex a "Reduce" rating, with a price target of $630.00. Scilex focuses on non-opioid pain management products, including ZTlido, ELYXYB, and GLOPERBA.</p>

Scilex (NASDAQ:SCLX) Posts Earnings Results, Misses Expectations By $21.76 EPS